Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Polkadot drops 9% to $1.10 as leveraged traders pull back

Polkadot drops 9% to $1.10 as leveraged traders pull back

AMBCryptoAMBCrypto2026/10/07 21:30

Polkadot [DOT] has had a rough day, being hit on all fronts. What’s going on?

The story behind DOT’s massive fall

Most of the damage happened fast.

DOT was at $1.21 on October 6. It went on to drift lower into the night, then fell off a cliff. In a few minutes, it went from about $1.19 to near $1.12.

@media only screen and (min-width: 0px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 50px; transition: min-height 0.3s ease; } } @media only screen and (min-width: 640px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 90px; } }
AD

There was a small bounce to $1.14 a few hours later. It didn’t hold.

DOT has been leaking lower all day. At the time of writing, we were at $1.106; down about 9.15% from where the slide began.

Who got hit? The futures market will tell you.

Open interest went from $91 million to about $85 million during the crash, meaning that leveraged positions got taken out in a hurry. But it has since gone back to around $87.4 million.

Funding rates also turned negative, dropping to -0.0016% at the time of this writing, despite being positive for most of the past week. Traders who were happy betting on DOT going up a few days ago are now paying to bet it goes down as a result of the recent trend.

There’s some news in the background…

This is Polkadot’s own stablecoin, along with a DOT/dotUSD liquidity pool funded with $2.5 million each in USDT and DOT. At the time of this writing, the proposal has been approved with about 98.4% Aye versus 1.6% Nay.

Polkadot has also been inviting developers to come and try its Devnet [a testing ground before mainnet].

The DOT sell-off came despite different ecosystem developments in the background, but this doesn’t mean that either was driving DOT’s short-term price action.

DOT’s market cap, meanwhile, is around $2 billion. That’s 96% below its 2021 peak of $52 billion, and still about 240,000x its yearly revenue.

A stablecoin could give the network more to do, but until then, traders can only watch how DOT trends.

Final Summary

  • Polkadot fell about 9% in the last day.
  • Polkadot’s on-chain revenue isn’t telling the whole story.

 

News Image 0News Image 1News Image 2
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.

The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)

路透社•2026/10/08 12:56

Oppenheimer Adjusts Acuity Price Target to $415 From $440, Maintains Outperform Rating

08:51 AM EDT, 10/08/2026 (MT Newswires) -- Acuity Brands (AYI) has an average rating of overweight and mean price target of $400.57, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

MT newswire•2026/10/08 12:51

BUZZ-Pacira BioSciences stock surges on Viatris' $1.65 billion acquisition deal

On October 8, Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30 as Viatris (VTRS.O) announced it will acquire Pacira BioSciences for $1.65 billion in cash, at a price of $36.50 per share. This offer represents a premium of approximately 44.8% over Pacira's last closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris’ product portfolio. Both parties expect the deal to be completed by the end of 2026. As of the previous trading day’s close, PCRX was down 2.6% year-to-date.

路透社•2026/10/08 12:31

BUZZ - Devon Energy shares rise after the company agrees to sell Eagle Ford assets for $4.2 billions

October 8 - Oil and gas producer Devon Energy (DVN.N) rose 2.65% in pre-market trading to $49.15. The company announced it would sell its Eagle Ford assets to Crescent Energy (CRGY.N) for $4.2 billions in cash. Devon's Eagle Ford assets include approximately 90,000 net acres in Texas, representing about 4% of its total oil equivalent production. This asset divestiture comes as the company, following its merger with Coterra Energy, faces investor pressure to streamline its asset portfolio and focus on its core Permian Basin business. The transaction is expected to be completed around the end of 2026. CRGY shares fell 2% to $13.20; the company also announced a $1 billions stock offering to raise funds for the DVN transaction. As of the previous trading day’s close, DVN shares had surged 30.71% year-to-date.

路透社•2026/10/08 12:26